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Abstract Although cranial radiotherapy is considered the
standard treatment for brain metastasis (BM), EGFR tyr-
osine kinase inhibitors (TKIs) have shown promising
activity in EGFR mutant non-small cell lung cancer
(NSCLC) patients with BM. However, the efficacy of
sequential cranial radiotherapy in patients with EGFR
mutant NSCLC who are treated with EGFR TKIs remains
to be determined. Patients with NSCLC who harbored an
EGFR mutation and whose BM had been treated with
EGFR TKIs were retrospectively reviewed. The clinical
outcomes of patients treated with EGFR TKIs alone and
those treated with cranial radiotherapy followed by EGFR
TKIs (additive therapy) were compared. Of the 573
patients with NSCLC with BM who harbored an EGFR
mutation and had received EGFR TKIs, 121 (21.1 %) had
BM at the time of initial diagnosis. Fifty-nine (49 %)
patients were treated with additive therapy, whereas 62
(51 %) patients were treated only with EGFR TKIs. No
significant differences were observed between the additive
therapy group and the EGFR TKI alone group regarding
intracranial progression-free survival (PFS) (16.6 vs
21.0 months, p = 0.492) or extracranial PFS (12.9 vs
15.0 months, p = 0.770). The 3-year survival rates were
similar in both groups (71.9 vs 68.2 %, p = 0.675).
Additive therapy consisting of cranial radiotherapy fol-
lowed by EGFR TKI treatment did not improve OS or
intracranial PFS compared with EGFR TKI treatment alone
in EGFR mutant NSCLC patients with BM. Further
prospective studies are needed to determine the precise
benefits of sequential cranial radiotherapy in EGFR mutant
NSCLC treated with EGFR TKIs.
Keywords Non-small cell lung cancer (NSCLC)  Brain
metastasis  Epidermal growth factor receptor (EGFR) 
Tyrosine kinase inhibitor (TKI)  Whole brain radiation
therapy (WBRT)  Stereotactic radiosurgery (SRS)
Introduction
Approximately, 20–40 % of all patients with non-small cell
lung cancer (NSCLC) present with brain metastasis (BM)
at the time of diagnosis or develop BM during their disease
course [1, 2]. The incidence of BM in patients with epi-
dermal growth factor receptor (EGFR) mutant advanced
NSCLC is higher than in patients with wild type EGFR
over the disease course [3]. Moreover, the longer survival
achieved with effective treatments such as EGFR tyrosine
kinase inhibitors (TKIs) in EGFR mutant NSCLC is asso-
ciated with a higher incidence of brain metastasis during
the disease course.
Whole brain radiation therapy (WBRT) has been con-
sidered the standard treatment for BM, but usually results
in neurologic sequelae such as neurocognitive dysfunction.
Stereotactic radiosurgery (SRS) is a novel technique that is
usually indicated in patients with oligo-brain metastasis.
This technique reduces the radiation damage to the
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surrounding normal brain tissue, thereby resulting in less
neurologic toxicity. Previous studies have demonstrated
that supplementation of WBRT with SRS treatment does
not confer any overall survival (OS) benefit compared with
WBRT alone [4, 5]. In general, the prognosis of patients
with BM in NSCLC remains poor (median survival time
3–6 months), even when active treatments such as WBRT
and SRS are given [6, 7].
Achieving a detailed understanding of the molecular
pathways of lung cancer has improved the clinical out-
comes of patients with NSCLC [8]. Patients with NSCLC
who harbor mutations in the epidermal growth factor
receptor (EGFR) have been shown to exhibit high sensi-
tivity to EGFR tyrosine kinase inhibitors (TKIs) [9, 10]. A
number of recent large randomized phase III trials com-
pared EGFR TKIs such as gefitinib, erlotinib, and afatinib
with systemic chemotherapy. These trials consistently
demonstrated higher response rates and longer progression-
free survival (PFS) with EGFR TKI treatment in patients
with EGFR mutant NSCLC, which resulted in EGFR TKIs
being used as the standard first-line therapy [11–13].
Although the brain-to-plasma concentration ratios of
EGFR TKIs are low (\1–3 %), several prospective studies
have demonstrated that EGFR TKIs show promising
activity, with a response rate of up to 80 % in patients with
EGFR mutant NSCLC and brain metastasis [14, 15].
Nevertheless, WBRT and SRS are still commonly used to
treat patients with BM before EGFR TKIs are used, even in
patients with asymptomatic brain metastasis. In this con-
text, the potential contribution of sequential cranial radio-
therapy in patients with EGFR mutant NSCLC who are
treated with EGFR TKIs remains to be determined.
Here, we performed a retrospective analysis to compare
the clinical outcomes of patients treated first with cranial
radiotherapy (WBRT or SRS) and then with EGFR TKIs




Clinical data were obtained by reviewing all pertinent
medical records from a database at Samsung Medical
Center. Between February 2005 to December 2013, data
from patients who had a confirmed EGFR mutation (exon
19 deletion or the L858R point mutation), histologically
proven NSCLC, clinical stage IIIB/IV or recurrent cancer
with brain metastasis at the time of initial diagnosis,
Eastern Cooperative Oncology Group performance status
0–2 and who were treated with EGFR TKIs (gefitinib or
erlotinib) as the first-line therapy were retrospectively
reviewed. Baseline patient characteristics collected for
analysis included age, sex, smoking history, ECOG per-
formance status, stage, number of metastasis sites, CNS
symptoms, type of EGFR mutation, and type of EGFR
TKI. Patients were treated with the recommended dose of
either gefitinib (250 mg per day; oral delivery) or erlotinib
(150 mg per day; oral delivery) until disease progression or
unacceptable toxicity was documented. Responses were
evaluated every 8 weeks with chest CT, while the patients
were on therapy. Brain MRI was repeated every 3 months
in patients who received SRS or WBRT, whereas it was
performed only when indicated for patients treated with
EGFR TKIs alone. Institutional review board approval was
obtained from Samsung Medical Center (SMC; Seoul,
Korea, 2016-02-005).
Cranial radiotherapy
Patients were classified into two groups. Group A consisted
of patients treated with cranial radiotherapy (WBRT or
SRS) followed by EGFR TKIs, whereas group B consisted
of patients treated with EGFR TKIs alone. WBRT was
delivered using megavoltage machines with photon beams
ranging from 4 to 10 MV through parallel opposed or 5
degree RAO–LAO fields that covered the entire cranial
content. The eyes were excluded from the beam by either
field arrangement or shielding. A dose of 2000 cGy was
given daily for 5 days over a single week, yielding a total
dose of 2000 cGy. SRS treatment involves a single high
dose of stereotactically focused radiation. Gamma knife
surgery consists of SRS using g-rays from radioactive
cobalt-60 installed in a Gamma Knife system (Eleka
Instruments, Stockholm, Sweden). EGFR TKI use was
discontinued during SRS and WBRT.
Statistical analysis
All available retrospective data were collected on a stan-
dardized data collection form. The objective of the present
study was to compare the clinical outcomes of patients
treated with cranial radiotherapy followed by EGFR TKIs
with those of patients treated with EGFR TKIs alone. The
primary outcome variable was OS. The secondary outcome
variables included intracranial and extracranial PFS. OS
was calculated from the start of EGFR TKI therapy until
death or the last follow-up. PFS was calculated from the
start of EGFR TKI therapy until disease progression, death
without documented progression, or the last follow-up.
Time to progression and survival were calculated using the
Kaplan–Meier method. The log-rank test was used to test
the significance of differences between the two groups.
A Cox proportional hazards regression model was used to
identify independent factors associated with OS or PFS.
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Two-sided p values \0.05 were considered to indicate
significance. All analyses were performed using SPSS ver.
22.0 (IBM Corporation) software.
Results
Patient characteristics
Between January 2005 and December 2013, 573 patients at
Samsung Medical Center who harbored an EGFR mutation
received an EGFR TKI for NSCLC with brain metastasis.
Among them, 121 patients (21.1 %) had brain metastasis at
the time of initial diagnosis. The median patient age was
60 years (range 30–86 years), and 69 % of the patients
were female. A total of 93 patients (77 %) were never
smokers, and 98 patients (81 %) had extracranial metas-
tasis at the time of diagnosis. The most common
extracranial metastasis site was bone (56 %). Patients were
treated with gefitinib (n = 103) or erlotinib (n = 18) as the
first-line therapy. Group A consisted of 59 patients who
were treated with additive therapy (32 with SRS, 26 with
WBRT, and 1 patient with both), whereas group B con-
sisted of 62 patients who were treated only with an EGFR
TKI. Brain metastasis-related symptoms were observed in
28 patients (47 %) in group A, whereas they were observed
in 12 patients (19 %) in group B. The number of patients
with C5 BMs was higher in group B (76 %) than in group
A (59 %). Twenty patients (17 %) had leptomeningeal
carcinomatosis that was confirmed by cerebrospinal fluid
cytology analysis (Table 1).
Treatment outcomes
The median follow-up duration time was 18.4 months
(range 0.4–47.9 months). Over this time, the median
overall survival had not been reached in either group by the
cutoff day (May 1, 2015). The estimated 3-year survival
rates were 71.9 % for group A and 68.2 % for group B
(p = 0.678) (Fig. 1). No significant differences were
observed between the two groups regarding intracranial
PFS (16.6 months in group A vs 21.0 months in group B,
p = 0.492) (Fig. 2) or extracranial PFS (12.9 months in
group A vs 15.0 months in group B, p = 0.770) (Fig. 3).
However, the intracranial disease control rate (sum of
complete response, partial response, and stable disease)
was higher in group A compared with group B (79.7 vs
59.7 %, p = 0.019). No significant differences were
observed between the two groups regarding the extracra-
nial disease control rate (93.2 % in group A vs 93.5 % in
group B, p = 0.942) or the objective response rate (sum of
complete response and partial response) (83.1 % in group
A vs 85.5 % in group B, p = 0.713). Salvage treatment of
intracranial disease, including additional SRS or WBRT,
was applied to a similar extent in both groups (11.9 % in
group A vs 24.2 % in group B, p = 0.08).
Subgroup analysis of group A revealed that the median
overall survival had not been reached in either group (SRS
or WBRT). The estimated 3-year survival rate was 81.4 %
for the SRS group and 62.2 % for the WBRT group
(p = 0.106) (Supplementary Fig. S1). No significant dif-
ference was observed between the WBRT group and the
SRS group regarding intracranial PFS (16.7 vs
15.6 months, p = 0.755) (Supplementary Fig. S2). Patients
who were treated with SRS had longer extracranial PFS
(16.3 vs 10.1 months, p = 0.008) compared with patients
who were treated with WBRT (Supplementary Fig. S3).
One patient who was treated with both SRS and WBRT
was excluded from our analysis (n = 1).
Prognostic factors
Multivariate analysis revealed that the number of BMs
(C5) [hazard ratio (HR) 3.36; 95 % CI 1.25–9.08,
p = 0.016] and poor ECOG PS (2) (HR 3.66, 95 % CI
1.73–7.74, p = 0.001) were both independent factors for
predicting poor OS. In addition, coexisting leptomeningeal
carcinomatosis was an independent factor for predicting
poor intracranial PFS (HR 1.79, 95 % CI 1.03–3.12,
p = 0.04). Other variables such as sex, age (\65 vs
C65 years old), specific EGFR TKI (gefitinib vs erlotinib),
and extracranial metastasis (none vs present) did not
influence survival outcome (Table 2).
Discussion
The brain is the one of the most common metastatic sites in
lung cancer. The incidence of brain metastasis in patients
with EGFR mutations is increasing due to the prolonged
overall survival times achieved with effective targeting
agents. Specifically, the use of EGFR TKIs extends sur-
vival times, thus allowing time for brain metastasis to
develop. WBRT has been considered the standard treat-
ment for patients with NSCLC and BM, even when the
patients have asymptomatic or oligo-brain metastasis.
However, long-term side effects such as neurocognitive
dysfunction and memory loss often deter patients from
receiving further anticancer therapy [16]. At present, SRS
is widely used as an alternative treatment for oligo-brain
metastasis. This treatment is less invasive and allows for
precise tumor targeting, which minimizes the unintended
irradiation of the adjacent normal tissue [17, 18].
The results of large randomized trials have indicated
EGFR TKI treatment as the first-line therapy in patients
with EGFR mutant NSCLC [19–21]. Importantly, EGFR
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TKIs can even cross the blood–brain barrier and have been
shown to accumulate in brain metastatic lesions [22]. These
compounds have also been shown to improve OS and
intracranial PFS in patients with EGFR mutant NSCLC
[6, 7, 23]. Given the inconsistent results obtained with the
concurrent use of EGFR TKIs and cranial radiotherapy
[24–27], the optimal management of patients with EGFR
mutant NSCLC with brain metastasis remains to be
determined.
Table 1 Patient baseline
characteristics (N = 121)
Group A (n = 59) n (%) Group B (n = 62) n (%) Total (n = 121) n (%)
Sex
Male 23 (39) 15 (24) 38 (31)
Female 36 (61) 47 (76) 83 (69)
Age (years)
Median (range) 60 (30–86) 60 (33–80) 60 (30–86)
\65 43 (73) 37 (60) 80
C65 16 (27) 25 (4) 41
Smoking status
Never 45 (76) 48 (78) 93 (77)
Prior 10 (17) 12 (19) 22 (18)
Current 4 (7) 2 (3) 6 (5)
ECOG PS
0 5 (9) 4 (7) 9 (7)
1 36 (61) 43 (69) 79 (65)
2 18 (30) 15 (24) 33 (28)
EGFR mutation
Exon 19 deletion 39 (66) 35 (57) 74 (61)
Exon 21 L858R 20 (34) 27 (43) 47 (39)
EGFR TKI
Gefitinib 54 (91) 49 (79) 103 (85)
Erlotinib 5 (9) 13 (21) 18 (15)
Extracranial metastasis
None 19 (32) 4 (7) 23 (19)
One 18 (31) 28 (45) 46 (38)
CTwo 22 (37) 30 (48) 52 (43)
Site of extracranial metastasis
Bone 28 (48) 40 (65) 68 (56)
Lung 17 (29) 22 (36) 39 (32)
Liver 10 (17) 10 (16) 20 (17)
Pleura 6 (10) 17 (27) 23 (19)
Adrenal gland 9 (15) 2 (3) 11 (9)
Other 4 (7) 5 (8) 9 (7)
Number of BMs
\5 21 (36) 15 (24) 36 (30)
C5 38 (64) 47 (76) 85 (70)
Co-existing LMS
Yes 10 (17) 10 (16) 20 (17)
No 49 (83) 52 (84) 101 (93)
BM-related symptoms
Yes 28 (48) 12 (20) 40 (33)
No 31 (52) 50 (80) 81 (67)
ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor
receptor, TKI tyrosine kinase inhibitor, BM brain metastasis, LMS leptomeningeal carcinomatosis
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In the present study, 21 % of all patients presented with
brain metastasis at the time of diagnosis, a finding that is
consistent with previous results [28]. However, no signifi-
cant difference was observed between patients treated with
an EGFR TKI versus patients treated with a additive
therapy of EGFR TKI treatment and cranial radiation
regarding overall survival. The estimated 3-year OS rates
were similar in both groups (71.9 % for group A and
68.2 % for group B). In addition, no significant differences
were observed between the two groups regarding
intracranial PFS or extracranial PFS, although the
intracranial disease control rate was slightly higher in
group A than in group B. The median intracranial PFS
times in both groups were greater than 18 months, which is
a quite promising result, considering that all of the patients
had brain metastasis. Moreover, the finding that EGFR TKI
treatment alone achieved a prolonged intracranial PFS of
21.0 months was quite remarkable, considering that the
EGFR TKI alone group had more patients with a high
number of brain metastases (C5) compared with the
additive therapy group (76 vs 64 %). We also found that
patients treated with SRS had a higher estimated 3-year OS
rate compared with patients treated with WBRT (81.4 vs
62.2 %). One possible explanation for this finding is that
the number of patients with many brain metastases (using a
cutoff of 5) was much lower in patients treated with SRS
than in patients treated with WBRT (47 vs 88 %).
Although additive therapy resulted in a higher
intracranial disease control rate (79.7 vs 59.7 %), addi-
tional salvage treatment was required for progressive
intracranial lesions to a similar extent in both groups
(11.9 % in group A vs 24.2 % in group B, p = 0.08). The
optimal timing and modality of cranial radiotherapy thus
depend on each patient’s symptoms and signs of intracra-
nial disease.
A recent meta-analysis demonstrated that upfront cranial
radiotherapy plus systemic chemotherapy improved sur-
vival outcomes compared with EGFR TKI treatment alone
in patients with EGFR mutant NSCLC with BM [29].
However, this improvement was only noted in 2-year
overall survival and not in intracranial PFS or extracranial
PFS. Furthermore, limiting the analysis to six prospective
studies revealed no significant differences in intracranial
PFS or OS between cranial radiotherapy in additive with
EGFR TKI treatment versus EGFR TKI treatment alone,
which is consistent with the present study. Given the
heterogeneous nature of the data obtained in the single arm
Fig. 1 Kaplan–Meier survival curves. Overall survival of group A
(cranial radiotherapy plus EGFR TKI) and group B (EGFR TKI only)
Fig. 2 Kaplan–Meier survival curves. Intracranial progression-free
survival of group A (cranial radiotherapy plus EGFR TKI) and group
B (EGFR TKI only)
Fig. 3 Kaplan–Meier survival curves. Extracranial progression-free
survival of group A (cranial radiotherapy plus EGFR TKI) and group
B (EGFR TKI only). SRS stereotactic surgery, WBRT whole brain
radiation therapy
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studies included in the meta-analysis, the outcomes
achieved with upfront cranial radiotherapy followed by
EGFR TKI treatment should be compared in future ran-
domized controlled studies with those achieved with EGFR
TKI treatment alone in patients with EGFR mutant NSCLC
and brain metastasis.
The main strength of this study is the homogeneity of
the patient population. Specifically, all patients had an
EGFR mutation, brain metastasis at the time of diagnosis,
and underwent EGFR TKI therapy as the first-line
treatment.
However, the present study also has some limitations.
Given the retrospective nature of the analysis, undefined
bias and/or confounding factors might have affected the
clinical outcomes. For example, the decision to treat
patients with WBRT, SRS, or EGFR TKIs was at the dis-
cretion of the treating physicians, which may have led to
bias. Moreover, the follow-up intervals of brain imaging in
the two groups were not equal, which might have affected
our assessment of intracranial PFS. Finally, the sample size
was relatively small, which implies that our results should
be interpreted with caution.
In conclusion, additive therapy consisting of cranial
radiotherapy followed by EGFR TKIs did not improve
overall survival, intracranial PFS, or extracranial PFS
compared with EGFR TKI treatment alone in patients with
EGFR mutant NSCLC and brain metastasis. Further
prospective randomized studies are needed to define the
precise benefit of sequential cranial radiotherapy in this
patient population.
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